Patents by Inventor Mark Ensor

Mark Ensor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5HT3R antagonist for use in treating aneurysms and cardiovascular risk
    Patent number: 11986464
    Abstract: Methods of treating or reducing risk of aneurysm, reducing cardiovascular risk, reducing serum cholesterol, reducing serum triglycerides, and/or reducing atherosclerotic plague in a subject involve administering to the subject an effective amount of a 5HT3R antagonist.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: May 21, 2024
    Assignee: University of Kentucky Research Foundation
    Inventors: Lisa Cassis, Sean Thatcher, Yasir Alsiraj, Mark Ensor, Eric Blalock
  • 5HT3R Antagonist For Use in Treating Aneurysms and Cardiovascular Risk
    Publication number: 20220347161
    Abstract: Methods of treating or reducing risk of aneurysm, reducing cardiovascular risk, reducing serum cholesterol, reducing serum triglycerides, and/or reducing atherosclerotic plague in a subject involve administering to the subject an effective amount of a 5HT3R antagonist.
    Type: Application
    Filed: May 2, 2022
    Publication date: November 3, 2022
    Inventors: Lisa Cassis, Sean Thatcher, Yasir Alsiraj, Mark Ensor, Eric Blalock
  • INTEGRATED STRUCTURAL SOLAR MODULE AND CHASSIS
    Publication number: 20130160823
    Abstract: A solar module having a curved surface to facilitate shedding of accumulated snow and water. The module can also be angled to achieve the same. The module includes a housing with a curved or angled upper surface and solar cells are positioned within the housing.
    Type: Application
    Filed: December 21, 2011
    Publication date: June 27, 2013
    Applicant: SoloPower, Inc.
    Inventors: Bruce Khouri, Mustafa Pinarbasi, Mark Ensor, Robert Campbell
  • ROOF INTEGRATED SOLAR MODULE ASSEMBLY
    Publication number: 20130160824
    Abstract: A solar module having a curved surface to facilitate shedding of accumulated snow and water. The module can also be angled to achieve the same. The module includes a housing with a curved or angled upper surface and solar cells are positioned within the housing.
    Type: Application
    Filed: June 8, 2012
    Publication date: June 27, 2013
    Applicant: SoloPower, Inc.
    Inventors: Bruce Khouri, Mark Ensor
  • PEG-modified uricase
    Patent number: 6913915
    Abstract: The present invention is directed to uricase modified with polyethylene glycol and to methods of treating different illnesses characterized by increased circulating uric acid levels, including but not limited to, hyperuricemia and tumor lysis syndrome.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: July 5, 2005
    Assignee: Phoenix Pharmacologics, Inc.
    Inventors: Charles Mark Ensor, Mike A. Clark, Frederick Wayne Holtsberg
  • Novel mutated form of arginine deiminase
    Publication number: 20040258675
    Abstract: The present invention discloses arginine deiminase that is genetically modified for more efficient manufacturing and processing. The present invention discloses recombinant DNA molecules and vectors and other therapeutic and pharmaceutical compositions. The present invention also discloses methods for preparing modified arginine deiminase as well as methods of treating cancer and other disease states using modified arginine deiminase.
    Type: Application
    Filed: August 21, 2003
    Publication date: December 23, 2004
    Applicant: Phoenix Pharmacologics, Inc.
    Inventors: Charles Mark Ensor, Frederick Wayne Holtsberg, Mike A. Clark
  • Mutated form of arginine deiminase
    Patent number: 6635462
    Abstract: The present invention discloses arginine deiminase that is genetically modified for more efficient manufacturing and processing. The present invention discloses recombinant DNA molecules and vectors and other therapeutic and pharmaceutical compositions. The present invention also discloses methods for preparing modified arginine deiminase as well as methods of treating cancer and other disease states using modified arginine deiminase.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: October 21, 2003
    Assignee: Phoenix Pharmacologies, Inc.
    Inventors: Charles Mark Ensor, Frederick Wayne Holtsberg, Mike A. Clark
  • PEG-modified uricase
    Publication number: 20030082786
    Abstract: The present invention is directed to uricase modified with polyethylene glycol and to methods of treating different illnesses characterized by increased circulating uric acid levels, including but not limited to, hyperuricemia and tumor lysis syndrome.
    Type: Application
    Filed: August 2, 2001
    Publication date: May 1, 2003
    Inventors: Charles Mark Ensor, Mike A. Clark, Frederick Wayne Holtsberg